Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma

Authors: Chugh, Seema ^{a, b, 1}, Tien, Jean C. ^{a, b, 1}, Hon, Jennifer ^{a, b}, Kenum, Carson ^{a, b}, Mannan, Rahul ^{a, b}, Cheng, Yunhui ^{a, b}, Li, Chi Chiang ^{a, b}, Taher, Zainab I. ^{a, b}, Delekta, Andrew D. ^{a, b}, Bawa, Pushpinder Singh ^{a, b}, Apel, Ingrid J. ^{a, b}, Miner, Stephanie J. ^{a, b}, Cao, Xuhong ^{a, b}, Mehra, Rohit ^{a, b}, Dhanasekaran, Saravana M. ^{a, b}, Qiao, Yuanyuan ^{a, b}, Mody, Rajen ^{a, c}, Chinnaiyan, Arul M. ^{a, b, d, e, f, ⁎}

Source: In Neoplasia February 2025 60